Yemaachi Launches Sheba HPV Test for screening of high risk HPV variants that cause cervical cancer
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
November 3, 2021
First study to monitor COVID-19 vaccine-induced immune responses in Africa
January 27, 2022
ACCRA (Citi Newsroom) –
Yemaachi Biotechnology, Africa’s Cancer Research Company has introduced the Sheba HPV Test, an effective home sampling kit to test for high-risk Human Papillomavirus (HPV) which is responsible for 99% of cervical cancer cases.
The Sheba HPV Test is an innovative product that identifies women who are at high risk for cervical cancer, which is currently the second most prevalent cancer in Ghanaian women, killing approximately 2000 every year. However, when detected early, cervical cancer is highly successfully treatable.
Related posts
March 21, 2022
